Core Insights - Firefly Neuroscience, Inc. is advancing research to identify ADHD subtypes using AI-powered EEG/ERP technology, which may enhance treatment personalization and monitoring [1][4][5] - The ADHD treatment market in the U.S. is estimated to exceed $10 billion, highlighting the significant unmet needs in accurate diagnosis and treatment [1] - Firefly's platform is based on a growing database of over 191,000 brain scans, aiming to create the world's first EEG/ERP brain foundation model [1][5] Company Developments - Firefly's technology aims to distinguish between the three main ADHD subtypes: hyperactive and impulsive, inattentive, and combined, which could lead to more effective treatment strategies [1][4] - The company has received FDA-510(k) clearance for its Evoke System, which is integral to its research and development efforts [1] - Firefly's Chief Technology Officer emphasized the potential for personalized treatment recommendations based on subtype-specific biomarker profiles [4] Industry Context - Current ADHD diagnoses rely heavily on subjective symptom checklists and the DSM-5-TR criteria, which may not adequately address the nuances of the disorder [2][3] - The introduction of objective biological markers for ADHD could revolutionize the clinical approach to treatment, improving outcomes for patients [1][4] - The use of AI and EEG/ERP technology in neuroscience is positioned to transform diagnostic and treatment monitoring methods for various neurological and mental health conditions [5]
Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD